Table 1 Baseline characteristics of the trial cohort. Data presented are numbers (%) or mean (standard deviation) for normally distributed variables and median (Q1-Q3) for skewed variables
Variable | Empagliflozin (n = 20) | Placebo (n = 22) | Missing |
|---|---|---|---|
Age (years) | 67 (8) | 68 (8) | 0 |
Male sex | 16 (80%) | 18 (82%) | 0 |
Waist circumference (cm) | 100 (95, 105) | 102 (95, 108) | 6 |
BMI (kg/m2) | 27.0 (4.1) | 27.1 (4.2) | 0 |
Medical history | |||
Index event (MI/UA) | 17/3 | 19/3 | |
Prior TIA/Stroke | 2 (10) | 0 (0) | 0 |
Peripheral artery disease | 1 (5) | 0 (0) | 0 |
Heart failure | 1 (5) | 0 (0) | 0 |
Known family history of CVD** | 5 (26) | 9 (45) | 3 |
Known family history of T2DM** | 5 (28) | 6 (29) | 3 |
Glycaemic group | |||
IGT | 11 (55%) | 14 (64%) | 0 |
T2DM | 9 (45%) | 8 (36%) | |
Smoking habits | 0 | ||
Current | 1 (5) | 7(32) | |
Previous (> 1 month) | 14 (70) | 12 (55) | |
Never | 5 (25) | 3 (14) | |
Blood pressure (mmHg) | |||
Systolic | 130 (16) | 131 (16) | 0 |
Diastolic | 80 (74, 85) | 80 (77, 85) | 0 |
Laboratory values | |||
LDL-C (mmol/L) | 1.43 (0.35) | 1.43 (0.59) | 1 |
HDL-C (mmol/L) | 1.24 (0.34) | 1.18 (0.38) | 1 |
Creatinine (µmol/L) | 85.9 (15.6) | 81.1 (18.4) | 1 |
eGFR (ml/min/1.73 m2) | 68.2 (12.6) | 72.9 (14.0) | 2 |
Haemoglobin (g/L) | 141 (135, 150) | 142 (135, 149) | 1 |
Troponin (ng/L) | 11.0 (9.0, 14.0) | 11.5 (10.0, 21.0) | 1 |
Triglycerides (mmol/L) | 1.0 (0.9, 1.4) | 1.2 (1.0, 1.4) | 1 |
hs-CRP (mg/L) | 1.1 (0.6, 1.7) | 1.1 (0.7, 1.4) | 1 |
NT-proBNP (ng/L) | 143 (72, 514) | 156 (62, 236) | 1 |
FPG (mmol/L) | 6.2 (6.0, 7.2) | 6.3 (6.0, 6.7) | 0 |
2 h-PG (mmol/L) | 10.7 (8.7, 12.2) | 9.7 (8.6, 12.3) | 1 |
HbA1c (mmol/mol) | 41 (39, 45) | 42 (40, 47) | 2 |
Mannose (µmol/L) | 92.7 (82.3, 97.6) | 86.1 (76.3, 90.1) | 4 |
Pharmacological treatment | |||
ACE inhibitors/ARBs | 17 (85) | 18 (82) | 0 |
Beta blockers | 17 (85) | 21 (95) | 0 |
Calcium channel blockers | 5 (25) | 4 (18) | 0 |
Diuretics | 7 (35) | 3 (14) | 0 |
Statins | 20 (100) | 21 (96) | 0 |
Aspirin | 19 (95) | 21 (95) | 0 |